Translate Bio (Translate Bio) Change In Other Working Capital : $256.4 Mil (TTM As of Jun. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Change In Other Working Capital?

Translate Bio's Change In Other Working Capital for the quarter that ended in Jun. 2021 was $-6.0 Mil. It means Translate Bio's Other Working Capital declined by $6.0 Mil from Mar. 2021 to Jun. 2021 .

Translate Bio's Change In Other Working Capital for the fiscal year that ended in Dec. 2020 was $253.2 Mil. It means Translate Bio's Other Working Capital increased by $253.2 Mil from Dec. 2019 to Dec. 2020 .

Translate Bio Change In Other Working Capital Historical Data

The historical data trend for Translate Bio's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Change In Other Working Capital Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Other Working Capital

0.18

0.95

44.88

-0.95

253.19

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Change In Other Working Capital	Get a 7-Day Free Trial														-5.16	298.63	-39.04	2.83	-5.98

Translate Bio Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $256.4 Mil.

Translate Bio Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Translate Bio's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109